Moneycontrol Bureau
Shares of Marksans Pharma spiked nearly 19 percent intraday Thursday after the UK health regulator allowed company to manufacture critical products at Goa plant.
"After company's response to observations, UK MHRA issued a restricted good manufacturing practice (GMP) certificate, allowing the company to continue manufacturing and marketing of critical products for the UK markets," says Mumbai-based pharma company in its filing.
The UK Medicines and Healthcare Products Regulatory Agency conducted GMP inspection of Goa plant from November 23 to November 25, 2015.
Marksans says restricted GMP status will continue until MHRA's next inspection, adding next reinspection can be as early as when the qualified person EU(QP) certifies site to be inspection ready. Once reinspected, the same can be reinstated to GMP compliant status, it says.
In an interview to CNBC-TV18, Mark Saldanha, CFO, Marksans Pharma says the company can manufacture and market 80-90 percent products from the Goa unit to the United Kingdom, adding that the sales to USA will continue as per normal.
At 15:03 hours IST, the scrip of Marksans Pharma was quoting at Rs 54.20, up Rs 6.90, or 14.59 percent amid high volumes on the BSE.Posted by Sunil Shankar Matkar
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
